Overview

Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to investigate tolerability/safety of repeated weekly doses of AZD8848 administered intranasally to seasonal allergic rhinitis patients.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca